ApopLogic Pharmaceuticals, LLC
ApopLogic Pharmaceuticals, LLC, is a startup phase biopharmaceutical company focused on the discovery, development and commercialization of products to treat cancer. The Company was formed in 2005 to capitalize on the intellectual property of its Founding Scientists, University of Colorado Health Sciences Center (UCHSC) faculty Drs. Richard Duke, Donald Bellgrau, Paul Bunn, Daniel Chan, Lajos Gera, Jaime Modiano, and John Stewart. ApopLogic takes advantage of its Scientists’ understanding of receptors and ligands that control natural cell death (apoptosis). Put most simply, ApopLogic helps cancer cells to commit suicide. For more information, please contact Richard Duke at richard.duke@apoplogic.com or go to www.apoplogic.com.

bioNovo
Bionovo (BNVI.OB) is a pharmaceutical company, founded in 2002, that discovers and develops drugs for cancer treatment and women's health. Bionovo is a leader in systems-biology integration with candidates designed to address the regulation of pathological conditions. Bionovo is working simultaneously on two distinct discovery approaches, one focusing on pro-apoptotic (causing cell death) agents for cancer, and a second focuses on selective estrogen-receptor modulators (SERMS) for indications in women’s health. Bionovo’s two lead candidates, BZL101, for advanced breast cancer, and MF101, for severe vasomotor symptoms of menopause, are currently entering Phase 2 trials.

Headquartered in Emeryville, California, the company has strong collaborations with leading US academic research centers including the University of California, San Francisco, University of Colorado Health Sciences Center, University of California, Berkeley and the University of Texas Southwestern. The strong ties to investigators within these institutions are deeply rooted in the technologies and scientific applications developed through common research programs. Such programs have been at the core of all our basic and clinical research. For more information please call 720-859-4117 or visit our website at www.bionovo.com

Cardiovascular Institute (CUCVI)
The Cardiovascular Institute is a collaboration of scientists from the University Colorado Health Sciences Center and CU-Boulder, with research directed toward identifying new treatment approaches to cardiovascular disease. For more information, please contact Luisa Mestroni in Suite 150 at 303-724-0577 or luisa.mestroni@uchsc.edu

ClinImmune Labs
ClinImmune Labs comprises five laboratories:
- Histocompatibility
- Clinical Immunology
- Flow Cytometry
- University of Colorado Cord Blood Bank
- Human Stem Cell Processing Facility

These laboratories provide services to kidney, heart, lung, liver, pancreas, islets and hematopoietic stem cell transplant programs around the world. For more information, please contact Brian Freed, Ph.D., Executive Director, at 303-724-0535 or brian.freed@uchsc.edu or http://www.clinimmune.com.

CU Technology Transfer
Services Provided by the TTO to the CU Research and Inventor Community:
The CU TTO works with researchers and inventors at various stages during the research and technology transfer process. The TTO helps researchers with arrangements to access and share proprietary information (through confidentiality agreements) and research materials (through material transfer agreements), and to define IP terms and conditions in sponsored research agreements and consulting agreements. After an invention has been conceived, TTO works with inventors to: clarify the invention disclosure and identify the IP; ascertain if the IP is protectable and commercially viable; engage and assist external legal counsel to prepare the patent application and prosecute it; and contact and pursue innovative adopter companies and entrepreneurs to license the IP for further development, commercialization, and public use. Inventive activity and relationships with companies occurs in an intensely legalistic environment and university researchers are encouraged to contact the TTO for assistance in crafting nondisclosure agreements, reviewing consulting contracts, and protecting their intellectual property and know-how.

For more information contact Jill Penafiel at 303-724-0221or e-mail Jill.Penafiel@cu.edu or website www.cusys.edu/techtransfer

Eurofins Medinet
Eurofins Medinet is a worldwide leader in its field of bioanalytical testing. With about $500 million annual sales and 5000 employees across 100 sites in 20 countries, Eurofins Scientific is a leading international group of laboratories providing an unparalleled range of testing and support services to the pharmaceutical, food, environmental and consumer products industries and to governments.

The Group offers a portfolio of over 15,000 reliable analytical methods for characterizing the safety, identity, purity, composition, authenticity and origin of products and biological substances. Through research and development, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical sciences to offer its customers unique testing solutions. For more information please contact Dr. Uwe Christians at uwe.christians@uchsc.edu

IHCtech
IHCtech offers a full line of custom quality animal and human tissue histopathology services from paraffin processing, embedding and sectioning, to plastic embedding of calcified bone and implanted tissues. Routine Hematoxylin and Eosin (H&E) staining as well as a large selection of special stains are offered. Specializing in Immunohistochemistry (IHC), we test antibodies, molecular probes, and biosensors in tissue or cells. We have a library of over 150 antibodies on hand we have validated. Let us process your tissue or cells with the care and expertise they deserve. To see all the details of our services and take a tour, visit our website at www.ihctech.net.

The Lindberg Center for Molecular Modeling and Bioinformatics
The Lindberg Center for Molecular Modeling and Bioinformatics (LCMMB) is a newly established core facility and part of the University of Colorado Cardiovascular Institute. The mission of the center is to provide the university community with resources and expertise in three areas of biomedical research: Structure-function studies using molecular modeling, bioinformatics, and genetic analysis on a collaborative basis. The LCMMB is equipped with state-of-art hardware and software related to its missions. The center is directed by Dr. Hamid Razzaghi, an Assistant Professor in the Division of Cardiology at the University of Colorado Health Sciences Center.

For more information contact Hamid Razzaghi in Suite128 at 303-724-1667 or hamid.razzaghi@uchsc.edu.

Lohocla
The mission of Lohocla Research Corporation (Lohocla) is to use genomic, proteomic, and gene array technology in conjunction with rational drug design for development of diagnostic and therapeutic products in the area of mental illness and/or addictive disorders. Within the next six years, the Company will license at least one drug candidate and establish a commercial clinical laboratory that utilizes the Company’s proprietary gene diagnostic markers to test for depression and addictive disorders in patients seeking professional care. For more information contact Dr. Boris Tabakoff in Lab 220 at 720-859-4082 or boris.tabakoff@uchsc.edu.

MBC Pharma, Inc.
MBC Pharma, Inc. is a biopharmaceutical company focused on discovering and developing drugs for bone diseases such as cancer and osteoporosis. MBC Pharma’s comprehensive and patented technology enables the highly efficient and specific delivery of drugs to bone. The approach has yielded promising lead structures in preclinical development for the treatment of multiple myeloma, metastatic bone disease caused by breast, prostate and lung cancer as well as osteoporosis and osteopenia.

For more information, visit our website at: www.mbcpharma.com

MycoLogics
MycoLogics is a company focused on developing vaccines against animal and human fungal and parasitic diseases. Our lead preclinical candidate is a vaccine to prevent Valley Fever in dogs; other vaccines to prevent aspergillosis or cryptococcosis for dogs and cats are in preclinical development.

PhosphoSolutions
PhosphoSolutions LLC. PhosphoSolutions was created to manufacture and distribute proprietary research tools, known as phospho-specific antibodies, which are at the cutting edge of proteomics. These antibodies are a key enabling technology used by biotech companies for both discovery and validation of new drugs. Founded by three of the world’s leading scientists in protein phosphorylation, the company’s unmatched expertise makes PhosphoSolutions the most qualified developer of custom-made phospho-specific antibodies. These antibodies greatly accelerate drug discovery and research in cancer and in neurological diseases such as Alzheimer’s. Contact Michael D. Browning at 720-859-4050 or e-mail mdb@phosphosolutions.com. www.phosphosolutions.com

ProTechSure Scientific, Inc.
There is a global increase in skin cancer as humans have more and more leisure time and alter both their lifestyles and clothing choices; further, increased UV exposure is occurring via thinning of the ozone layer, and non-melanoma skin cancers are now the most common malignancies in the U.S. with over 800,000 new cases reported each year. The goal of ProTechSure Scientific, Inc. is to develop a skin cream with both UV protection and the potential to reverse or slow cancer development. This would be an entirely new cosmetic; such a product could significantly impact the health of America.

Proteome Resources
Proteome Resources LLC is a manufacturer and provider of biochemistry tools and services for drug discovery and basic research. Presently, the company supplies 98% pure ubiquitin enzymes, ubiquitin derivatives, ubiquitin-like proteins (UBLs), ubiquitin antibodies, custom protein and peptide services, and apoptosis tools.

The company’s offering brings to market proven experience in enzyme production and unmatched expertise in UPS science. Since 1996, the University of Colorado has produced ubiquitin and other enzymes for research and transfer purposes, refining technology now licensed to the company. Company cofounder Dr. Ding Xue is a recognized expert in apoptosis and proteasome science, and the company’s advisory board contains some of academia’s most esteemed UPS scientists.

Proteome Resources is a Colorado Limited Liability Company with corporate headquarters and a manufacturing center in Denver. For more information contact Randy Swenson in Lab 216 at 720-859-4185 or randy@proteomeresources.com.

Sciona
Sciona is a privately held, international company that provides personalized health and nutrition recommendations based on an individual's diet, lifestyle and unique genetic profile (www.mycellf.com). Sciona was founded on a simple premise: to use the scientific information uncovered in the Human Genome Project for the benefit of consumers and consumer product companies. Sciona has built its business strategy around its patented application of evidence-based genetic information for the development of personalized products that help individuals optimize their health and has become a leader in nutrigenomics, the science of personalizing your nutrition and lifestyle choices to match your genes.

Taligen Therapeutics
Taligen Therapeutics, Inc. is a biotechnology company founded in March 2004 to develop and commercialize technology from the University of Colorado for the treatment of serious inflammatory disease. The Company employs innovative technologies to manipulate complement proteins of the immune system to inhibit inflammation and to target inhibitors of inflammation to specific sites of tissue injury. By targeting the complement system, Taligen's technology inhibits inflammation proximally, or upstream in the inflammatory cascade, such that blockade at a single step results in the down-regulation of multiple effector mechanisms.

The Company's technology can be applied to multiple inflammatory diseases. Based on medical need, the competitive landscape and pre-clinical data, Taligen's initial focus is on the major unmet medical need of severe refractory asthma. Taligen's products are currently in pre-clinical development, with an estimated filing of an IND in Q2 2007. The Company has received grant funding in excess of $1MM and closed a Series A round of financing that totaled $3.75 million in August 2005. The round was led by Sanderling Ventures, of San Mateo, California, and included High Country Ventures and Tango, both from Colorado. For more information contact Woody Emlen, MD at 303-638-1604 or wemlen@taligentherapeutics.com.

Touch of Life Technologies
Touch of Life Technologies (ToLTech) sells a full line of health education software under the name VH Dissector. The software is used in professional, graduate, and undergraduate anatomy programs. The software is installed in more than 140 institutions. The first major upgrade to the software has been shipping since August 2005. In the first quarter of 2006 ToLTech added two new products: 1. The Virtual Edge (Lessons that run on the VH Dissector) a pro-section guide for undergraduate anatomy, and 2. The Surface Palpation Guide (Lessons that run on the VH Dissector) that covers the techniques used to locate and palpate over 200 structures near the surface of the human body.

ToLTech has developed a knee arthroscopy simulator in partnership with the American Academy of Orthopaedic Surgeons. This simulator will go into validation testing in 2006. We are currently developing other procedural simulators in the areas of orthopedics, gastroenterology, rheumatology, radiology, ophthalmology, and general surgical procedures. For more information visit our website at www.ToLTech.net or 720-859-4140 or info@toltech.net

Vitro Diagnostics
Vitro Diagnostics, Inc., dba Vitro Biopharma (OTC Bulletin Board; VODG) develops and manufactures products for use in research, drug discovery and pharmaceutical applications. We presently manufacture and sell the VITROCELL™ brand of human cell lines for research use. We have also generated several human, adult stem cell lines and have recently developed methods that result in differentiation of functional beta cells from beta islet stem cells. We are preparing to launch stem cell-derived human beta islet cells and associated reagents and derivatives as an extension of the VITROCELL™ product line.

Stem cell-derived human beta islet cells represent a potential indefinite supply of cellular material for use in transplantation therapy of diabetes. While recent clinical trials have shown the effectiveness of beta islet transplants in the treatment of diabetes, these studies are limited by an insufficient supply of pancreas tissue and by immune rejection of transplanted tissues. Vitro is engaged in development of its pancreatic stem cell lines and differentiation processes for cell therapy of diabetes. These studies initially involve transplantation into diabetic animals and additional pre-clinical studies.

Vitro also owns proprietary technology and products for use in the treatment of human infertility. These products include various forms of purified human FSH and an injection device for use in the administration of these drugs.

We maintain a website at www.vitrodiag.com. Please contact Jim Musick, Ph.D. at (720) 859-4120 for additional information.